90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

This clinical trial will compare 1-year outcomes in patients with hypoalbuminemia and a new diagnosis of small, early-stage hepatocellular carcinoma (HCC) who are candidates for both 90-Yittrium Therasphere transarterial radioembolization (90Y) and microwave ablation (MWA). The study will determine whether treatment with 90Y lowers the risk of disease progression within the first year after diagnosis. Participants will be randomized to receive either first cycle 90Y or MWA and then proceed with standard of care.

Trial Details

NCT ID
NCT05953961
Phase
NA
Sponsor
Ochsner Health System
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Therasphere 90Y
  • Microwave Ablation
Locations (sample)
  • New Orleans, Louisiana, United States|29.95465,-90.07507

Key Eligibility Criteria

  • HCC diagnosis according to the Liver Imaging - Reporting Data System (LI-RADS) Criteria as defined in the American Association for the Study of Liv…
  • Eastern Cooperative Oncology Group score 0 - 1
  • Child-Pugh A - B
  • Bilirubin \< 2.5 mg/dL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →